18F-AV-1451 Autopsy Study

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 13, 2018

Study Completion Date

July 15, 2018

Conditions
Alzheimer's Disease
Interventions
DRUG

Flortaucipir F18

370 megabecquerel (MBq) IV single-dose

PROCEDURE

PET Scan

positron emission tomography (PET) scan

Trial Locations (31)

3010

University of Melbourne, Parkville

12801

Adirondack Medical Research Center, Glens Falls

13210

Clarity Clinical Research, LLC, Syracuse

27157

Wake Forest School of Medicine, Winston-Salem

27710

Duke University Medical Center, Durham

30329

Emory University Brain Health Center, Atlanta

32806

Bioclinica, Orlando

32952

Merritt Island Medical Research, Merritt Island

33016

Galiz Research, Hialeah

33137

Miami Jewish Health Systems, Miami

33185

D de la Vega MD Research Group, Miami

33912

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

44119

Hospice of the Western Reserve, Cleveland

45459

Valley Medical Primary Care, Centerville

73112

American Clinical Trials, LLC (Site 1216), Oklahoma City

Oklahoma Behavioral Health, Oklahoma City

77030

Houston Methodist Research Institute, Houston

78028

Sante Clinical Research, Kerrville

85006

Banner Alzheimer's Institute, Phoenix

85013

St. Joseph's Hospital and Medical Center, Phoenix

89052

Steinberg Diagnostics, Henderson

92103

California Research Foundation, San Diego

Pacific Research Network, San Diego

92658

Hoag Memorial Hospital Presbyterian, Newport Beach

92705

Syrentis Clinical Research, Santa Ana

94114

Ray Dolby Brain Health Center, San Francisco

95032

Cherlin Research, Los Gatos

98004

Overlake Internal Medicine Associates, PS, Bellevue

98104

University of Washington Medicine, Seattle

02169

Alzheimer's Disease Center, Quincy

02903

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY